Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Melanoma is a significant cause of cancer mortality.
• Targeted therapies are crucial for improving melanoma treatment outcomes.
• Aurora kinase A (AURKA) is implicated in melanoma progression.

Purpose of the Study:

• To investigate the anti-cancer effects of Alisertib (ALS), a selective AURKA inhibitor, in melanoma.
• To elucidate the molecular mechanisms underlying ALS's efficacy in melanoma cells.
• To evaluate the potential of ALS as a therapeutic agent for melanoma.

Main Methods:

• Utilized A375 and skmel-5 melanoma cell lines.
• Administered Alisertib (ALS) and SB202190 (p38 MAPK inhibitor).
• Assessed cell proliferation, apoptosis, autophagy, and cell cycle progression.
• Performed p38 MAPK knockdown experiments.

Main Results:

• ALS demonstrated anti-proliferative, pro-apoptotic, and pro-autophagic effects in melanoma cells.
• ALS inhibited p38 MAPK signaling, leading to cell cycle arrest via the p53/p21/cyclin B1 pathway.
• SB202190 enhanced ALS-induced apoptosis and autophagy.
• p38 MAPK knockdown amplified ALS-induced apoptosis but reduced autophagy.
• Autophagy inhibition sensitized melanoma cells to ALS-induced apoptosis.

Conclusions:

• Alisertib (ALS) exhibits significant anti-melanoma activity.
• ALS exerts its effects through modulation of p38 MAPK signaling, cell cycle regulation, and induction of apoptosis and autophagy.
• ALS represents a potential therapeutic candidate for melanoma treatment.